NXTS Nexentis Technologies Inc.
$1.65 -4.07%
Updated
Healthcare · Pharmaceutical Preparations
Nexentis Technologies Inc. (NXTS) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $2 million. Shares last traded at $1.65, 93.1% below their 52-week high. Revenue declined 20.2% year over year.
Market Cap
$2M
Shares Out
1.5M
EPS (TTM)
$-174.49
P/E Ratio
—
P/S Ratio
11.42
P/B Ratio
1.26
Dividend / Share
—
Dividend Yield
—
52-Week High
$23.80
52-Week Low
$0.57
Volume
35
Avg Vol (3m)
18,818.683
Performance
1W
-10.81%
1M
-1.79%
3M
-69.78%
6M
—
YTD
—
1Y
—
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
RSI (14)
34.85
SMA (50)
$2.74
SMA (200)
—
Price vs SMA50
-39.79%
Price vs SMA200
—
ATR (14)
$0.24
Financials
Revenue
$0M
Net Income
$-16M
Gross Margin
21.4%
Operating Margin
—
Net Margin
—
Return on Equity
-841.3%
Return on Assets
-85.7%
Current Ratio
3.72
Debt / Equity
0.00
Revenue Growth (YoY)
-20.2%
Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $-25.14 | 2026-08-13 |
| Q1 2026 | $-10.74 | 2026-05-14 |
| FY 2025 | $-8.61 | 2026-03-31 |
| Q3 2025 | $-8.23 | 2025-11-13 |
| Q2 2026 | $-130.38 | 2026-08-13 |
| Q1 2026 | $-85.25 | 2026-05-14 |
Pharmaceutical Preparations peers
NXTS vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated
P/S vs peers
11.42 / 11.11 med
+3% premium
1–14 of 14
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
| REGN | Regeneron Pharmaceuticals | $87.2B | 20.15 | 5.61 | 27.9% | -1.02% |
| TEVA | Teva Pharmaceutical Industries Ltd | $42.6B | 60.41 | 2.46 | 4.1% | -2.32% |
| ALNY | Alnylam Pharmaceuticals | $35.4B | 43.77 | 9.52 | 21.8% | -1.10% |
| ZTS | Zoetis | $31.5B | 12.05 | 3.31 | 27.5% | +0.16% |
| RPRX | Royalty Pharma Plc | $28.2B | 34.56 | 11.11 | 32.1% | +1.24% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.